US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Annovis Bio, Inc.

News headline image
Annovis to Host Patients’ Live Forum on February 27, 2025
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio, Inc. Announces Proposed Public Offering
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis to Host Year-End Investor Webcast on December 11, 2024
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
From Annovis Bio, Inc.
Via GlobeNewswire
News headline image
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
From Annovis Bio, Inc.
Via GlobeNewswire